Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2+ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib armcompared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER+)/ HER2+ tumors, suggesting bidirectional cross-talk between the ER and HER pathways.
ASJC Scopus subject areas
- Cancer Research